This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research to investigate the role of the Toxoplasma gondii parasite's cytoskeleton in its infection and reproduction process. The $441,750 award will fund a 24-month project at Boston College to study the molecular mechanisms involved in the early stages of the parasite's budding and division cycle. The research aims to establish the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $176,537 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the CAL Poly Pomona Foundation Inc., a nonprofit organization supporting California State Polytechnic University, Pomona. The award, effective July 24, 2024 through June 30, 2028, supports research to investigate the role of reactive oxygen species (ROS) in controlling acute Toxoplasma gondii infection. Specifically, the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $269,054 to the University of California, Merced to conduct research on host-parasite interactions and susceptibility mechanisms related to Toxoplasma gondii infection.
The project aims to leverage the Collaborative Cross mouse model and parasite genetics to identify novel host genes and gene interactions that govern disease outcome...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of South Florida a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the regulation of cell division in apicomplexan parasites. The $2,031,750 grant, awarded on April 12, 2024, supports a 5-year research project to study the unique cell cycle mechanisms of parasites like Plasmodium and Toxoplasma that cause significant human diseases. The project aims to...
This $207,170 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to characterize the role of a novel Plasmodium cytoskeletal protein, PFFIG, in the blood-stage life cycle of the malaria parasite Plasmodium falciparum. The primary objectives are to use inducible knockout systems and advanced microscopy techniques to investigate PFFIG's functions in parasite replication, daughter cell...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $520,809 to Rosalind Franklin University of Medicine & Science to investigate the role of TAM receptors in modulating the humoral immune response against parasitic infections, specifically malaria. The research seeks to understand how factors like systemic hypoxia and anemia induced by malaria infection impact TAM receptor expression on...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to understand the role of transmembrane proteins in the cell division process of the malaria parasite Plasmodium falciparum. The $147,656 award, effective from January 22, 2025 to October 31, 2027, will fund experiments at Boston Children's Hospital to investigate the localization and function of three key transmembrane proteins...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $244,440 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Albert Einstein College of Medicine in Bronx, New York. This funding will support a research project titled "Role of Cytolytic ZEB2+ Memory CD4+ T Cells in Protection Against Liver Stage Malaria." The project aims to use murine models to explore the kinetics, differentiation, functions, and protective...
This federal Project Grant award, valued at $214,742 and provided by the National Institute of Allergy and Infectious Diseases under CFDA 93.855 Allergy and Infectious Diseases Research, supports research to identify and characterize Toxoplasma gondii (T. gondii) proteins that enable the parasite to cross the placental barrier and cause congenital infection. The research team at Texas A&M University will use innovative methods, including an in vitro placental barrier model and pregnant...
This $125,250 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to elucidate the mechanisms regulating Wolbachia bacterial infections in Anopheles mosquitoes, the vectors of human malaria. The goal is to gain insights into the cytoplasmic incompatibility induced by Wolbachia that may prevent natural infections in Anopheles, with the aim of generating tools for Wolbachia-based...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $220,340 to the Whitehead Institute for Biomedical Research to conduct research focused on understanding the molecular mechanisms that regulate the chronic stage of the Toxoplasma gondii parasite. The key objectives are to investigate how the parasite's BFD1 and BFD2 proteins interact to drive and maintain the chronic stage, as well as to identify factors that trigger reactivation from this stage. This research aims to provide insights that could inform the development of therapies to combat persistent Toxoplasma infections, which affect an estimated 25% of the global population. The project will be carried out over a period of 3 years, from May 2024 to March 2027.